I de fire placebokontrolgruppeforsøg lå hazard ratio for generel overlevelse på mellem 1, 25 og 2, 47, til fordel for kontrolgruppen.
In the open-label study there was no difference in overall survival between patients treated with recombinant human erythropoietin and controls.